| __timestamp | Pfizer Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 9577000000 | 125883000 |
| Thursday, January 1, 2015 | 9648000000 | 69036000 |
| Friday, January 1, 2016 | 12329000000 | 72700000 |
| Sunday, January 1, 2017 | 11240000000 | 105700000 |
| Monday, January 1, 2018 | 11248000000 | 198700000 |
| Tuesday, January 1, 2019 | 10219000000 | 117600000 |
| Wednesday, January 1, 2020 | 8692000000 | 108100000 |
| Friday, January 1, 2021 | 30821000000 | 122500000 |
| Saturday, January 1, 2022 | 34344000000 | 146700000 |
| Sunday, January 1, 2023 | 29687000000 | 257500000 |
| Monday, January 1, 2024 | 17851000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Pfizer Inc., a global leader, has seen its cost of revenue fluctuate significantly over the past decade. From 2014 to 2023, Pfizer's cost of revenue surged by over 200%, peaking in 2022. This reflects the company's aggressive expansion and investment in new technologies. In contrast, United Therapeutics Corporation, a niche player, maintained a relatively stable cost structure, with a modest increase of around 100% over the same period. This stability highlights their focused approach in specialized markets. The stark contrast between these two companies underscores the diverse strategies within the pharmaceutical sector. As Pfizer navigates the complexities of a broad portfolio, United Therapeutics remains steadfast in its specialized niche, offering a fascinating study in strategic financial management.
Cost of Revenue: Key Insights for Novo Nordisk A/S and United Therapeutics Corporation
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs United Therapeutics Corporation
Analyzing Cost of Revenue: Pfizer Inc. and Sanofi
Cost of Revenue Trends: Pfizer Inc. vs BeiGene, Ltd.
Analyzing Cost of Revenue: Pfizer Inc. and Biogen Inc.
Cost of Revenue Comparison: Pfizer Inc. vs Cytokinetics, Incorporated
Cost of Revenue Trends: BeiGene, Ltd. vs United Therapeutics Corporation
United Therapeutics Corporation vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for United Therapeutics Corporation and Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down United Therapeutics Corporation and Cytokinetics, Incorporated's Expenses
United Therapeutics Corporation vs Xenon Pharmaceuticals Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: United Therapeutics Corporation and Iovance Biotherapeutics, Inc.